Dublin, November 10, 2021--(BUSINESS WIRE)--ResearchAndMarkets.com has added the "Global Health Products Market Outlook to 2026" report.

Hygiene products mainly include feminine hygiene, baby care, oral care, and hand and body care. It conducts electricity and is used to make electrodes, paints, batteries, pencil leads, etc. According to the publisher, the global hygiene products market is expected to witness significant growth during the forecast period. It is expected that during the forecast period, more and more infectious diseases and global pandemics and pandemic attacks will drive the market. In addition, increased awareness of feminine hygiene is expected to further upgrade the market. However, the environmental degradation issues associated with disposable sanitary napkins and diapers, as well as the decline in water quality due to the widespread use of surfactant-based hand sanitizers, may hinder market growth in the near future.

According to data from the World Health Organization, infectious diseases have claimed the lives of more than 17 million people in one year, and 30 new diseases have appeared in the world in the past 20 years. The outbreak of infectious diseases such as Covid-19, SARS, Ebola, and typical hospital-acquired infections, such as sepsis, claim the lives of many people every year. The convenience of world travel adds another group of infectious diseases, coupled with an aging population that is more susceptible to these diseases. Economists and futurists predict that by 2050, infectious diseases will become the world's number one killer, surpassing heart disease. Various pathogens, such as viruses, bacteria, fungi and parasites, continue to evolve and cause many diseases, which require major technologically advanced measures to deal with. The shortage of medical resources, lack of sanitation facilities and dense population have led to an increase in infectious diseases.

The global hygiene market is segmented according to type. The type breakdown is further subdivided into women, bathing and showering, hand care, oral cavity, baby care and others. Among various types, hand hygiene products are expected to dominate the market share in the near future, mainly due to the coronavirus pandemic. Due to changes in lifestyle, population growth, disposable income, and female labor force, feminine hygiene products and baby care products are also expected to surge.

The United States is the largest market economy in the world. Due to the ongoing coronavirus pandemic, the country's GDP will grow at an annual rate of 5% and 9.5% in the first and second quarters of 2020, respectively. In the United States, the personal care industry has reached new heights year by year. On average, women in the country use 12 personal care products every day, while men use 6 products. In 2018, the country sold nearly 6 billion tampons and used 50,000 to 15,000 sanitary napkins and tampons during a menstrual period in a lifetime. Many regions of the country have also initiated cost-based incentives and tax cuts for feminine hygiene products. Of the 45 states that levy sales tax, 9 states are exempt from tampon sales tax, including Connecticut, Florida, Illinois, Maryland, Massachusetts, Minnesota, New Jersey, New York and Pennsylvania.

The increase in the Covid-19 pandemic has largely promoted the development of the health products market. The outbreak of Covid-19 has caused widespread awareness of the personal hygiene product market in the region. Even before Covid-19 hit the United States, 60% of Americans were overly worried about contracting the flu. Nearly 64% of Americans believe that hand washing is more effective in removing bacteria than hand sanitizer.

4.2 Porter's five forces analysis

4.2.2 Potential of new entrants in the industry

7.12 TLC Hygiene Cosmetics Co., Ltd.

For more information about this report, please visit https://www.researchandmarkets.com/r/8ltkz8

View the source version on businesswire.com: https://www.businesswire.com/news/home/20211110005675/en/

ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com US Eastern Time Office Hours Call 1-917-300-0470 US/Canada Toll Free 1-800-526-8630 GMT Office Hours Call 353-1-416-8900

For most of the past two years, all the focus has been on the coronavirus, but these biotech companies also have big plans to develop vaccines against other diseases.

Alzheimer's stocks cassava and Cortexyme diverged on Thursday. An analyst said that SAVA stock was “back on track,” but CRTX stock fell.

According to CNBC, Moderna Inc (NASDAQ: MRNA) defended the use of its COVID-19 vaccine, saying that it provides protection that exceeds the risk of myocarditis in a small number of vaccinated young men. The FDA said last week that more time is needed to decide whether to approve Moderna's vaccine for children aged 12 to 17. The reported rare cases of heart inflammation in men under 30 years old after Moderna vaccine are relatively higher than those who received Pfizer (NYSE: PFE) and BioNTech

Novavax (NVAX)'s two doses of COVID-19 vaccine are gaining some momentum, starting with the provision of a series of emergency-use fillers worldwide, and it was authorized for the first time in Indonesia this month. According to CEO Stanley Erck, the company is expected to submit an application to the U.S. Food and Drug Administration (FDA) before the end of the year and has called for a meeting with the agency to advance the next step. Erck told Yahoo Finance Live on Wednesday that the company hopes to receive a response from the FDA "soon" and believes that Novavax may obtain up to five authorizations worldwide in the next 6-8 weeks. However, most of its actual dose distribution may begin in early 2022.

Our most respected CEO George Scangos, the President and CEO of Vir Biotechnology Inc., and his staff have redoubled their efforts during the pandemic to work with GlaxoSmithKline to produce a drug to treat Covid-19 patients.

The European Medicines Agency's Committee on Medicines for Human Use has recommended that Novo Nordisk A/S (NYSE: NVO) Wegovy be authorized for chronic weight management of adult obesity. Wegovy is a 2.4 mg injection of semaglutide once a week. CHMP’s positive opinion is based on the results of the STEP 3a trial program, which showed an average weight loss of 17-18% for 68 weeks. Wegovy demonstrated safe and well-tolerated profiles throughout the program, most of which

The surge in coronavirus cases in several states with relatively high vaccination rates in the United States has raised concerns among health officials who hope that vaccination will help contain the COVID-19 pandemic.

Some of the content you hear in those Medicare Advantage TV commercials is true, but the rules state that "free" is not really "free."

Pfizer (NYSE: PFE) has won the title of leader in the prevention of coronavirus vaccines. Now, Pfizer may be about to achieve leadership in another blockbuster field: Coronavirus treatment. The data is so strong that an independent monitoring committee recommended that Pfizer stop recruiting patients to participate in the trial - and seek regulatory authorization.

With strong earnings in the third quarter and the stock price returning to the key moving average, is AbbVie's stock worth buying? Can ABBV stock be bought now?

When you reach retirement age, Medicare insurance provides basic medical insurance coverage for your health needs. However, this coverage is basic and does not cover all the costs of covered medical services and supplies. The medical insurance supplementary insurance policy is... Continue reading → The average cost of medical insurance supplementary insurance posts first appeared on the SmartAsset blog.

The CMS Molecular Diagnostic Service Program (MolDX) has released the final local coverage determination (LCD) for pan-cancer immunotherapy monitoring using the Natera Inc (NASDAQ: NTRA) Signatera Molecular Residual Disease (MRD) test. The accompanying billing and coding article pointed out that, regardless of the tumor type, Medicare patients receiving immunotherapy can now use Signatera for serial tests. The last LCD used for immunotherapy monitoring is the second Medicare LCD covering Signater

The following is a summary of the main developments in the field of biotechnology in the past 24 hours: Focus stock Merck started a late-stage study of heart failure treatment Merck (NYSE: MRK) announced the launch of VICTOR, which is a key stage 3 Verquvo’s cardiovascular Clinical trials are conducted in patients with chronic heart failure whose ejection fraction is reduced by 40% or less and who have not experienced a recent worsening heart failure event. Gilead’s partner announces Phase 2b positive data for antibody-drug conjugates

COVID-19 cases in Vermont have surged to the highest level in the pandemic. Here is what health officials believe is happening.

Currently, nearly 90% of American adults 65 and older take at least one prescription drug. More than half (54%) of American seniors need four or more. For millions of people with Medicare drug plans, open registration may be an opportunity to review and find the best coverage for the coming year. Approximately 24 million Americans have an independent Medicare prescription drug (Part D) plan. Depending on where you live, there are 10 to 30 different plans to choose from. Compare your 2022 plan options

Researchers say that as many as one-third of mental health disorders are caused by childhood adversity.

"Strawberry Milk." View entire post ›

The company aims to help the human liver better control cholesterol. Its treatment is currently being tested in monkeys, but Verve hopes to start human trials next year.

TSHA earnings conference call as of September 30, 2021.

Prince Harry continued his long-term commitment to mental health in his touching speech to commemorate Veterans Day. November